Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What to expect today:
1. Longs adding to their position (I already added another 10,000 today)
2. Sideliners jumping in.
3. Shorts covering.
What does this spell? Well above $4.00/share today! Shoot...we might even hit $4.00 PREmarket! Wait until the market opens and major institutions start buying it!
Oh, and if we hit the $5.00 mark today (which we might), then institutional buying will really propel this stock up! It's a great time to be in ARIA!
Hardly...in the end that will turn out to be fluff. These days everyone files a lawsuit against everyone else. The lawsuit will not hurt the stock. It is more akin to white noise.
With this news, the share price should settle in somewhere between $4.50 and $6.00/share very soon. And if the shorts cover all at once, there might be a large spike in the price. Get ready folks!
This could give us a HUGE pop in share price. Shorts will have to cover beginning today! We have seen the bottom! Get ready for a massive couple weeks ahead as the price moves North.
Wait until the opening bell! There will be some major buying going on!
Congratulations longs! Things couldn't look better! It is going to be a merry Christmas!
ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias
3 minutes ago - DJNF
Recommendations made to minimize risk of occlusive vascular events
CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--November 22, 2013--
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced adoption of a positive opinion by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) on the continued availability of Iclusig(R) (ponatinib) in the EU for use in patients in its authorized indications. Following its review of updated clinical-trial data on Iclusig, the CHMP made a series of recommendations on measures to help minimize the risk of occlusive vascular events in patients taking Iclusig. The authorized indications of Iclusig, as approved in July 2013, are as follows:
-- The treatment of adult patients with chronic phase, accelerated phase or
blast phase chronic myeloid leukaemia (CML) who are resistant to
dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and
for whom subsequent treatment with imatinib is not clinically
appropriate; or who have the T315I mutation, or
-- The treatment of adult patients with Philadelphia-chromosome positive
acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib;
who are intolerant to dasatinib and for whom subsequent treatment with
imatinib is not clinically appropriate; or who have the T315I mutation.
The EMA has recommended the following:
-- Iclusig should not be used in patients with a history of heart attack or
stroke, unless the potential benefits of treatment outweigh the risks.
-- The cardiovascular status of patients should be assessed and
cardiovascular risk factors actively managed before starting treatment
with Iclusig. Cardiovascular status should continue to be monitored and
optimised during treatment.
-- Hypertension should be controlled during treatment with Iclusig, and
healthcare professionals should consider interrupting treatment if
hypertension is not controlled.
-- Patients should be monitored for evidence of vascular occlusion or
thromboembolism, and treatment should be interrupted immediately if this
occurs.
The EMA plans to conduct a further review of the benefits and risks of Iclusig and may make additional recommendations on how Iclusig should be used.
"We have been working closely with the EMA to provide updated clinical-trial data on patients treated with Iclusig," said Jonathan E. Dickinson, general manager, ARIAD Pharmaceuticals (Europe). "The conclusions reached by the CHMP, which were announced today, confirm a positive benefit-risk assessment for Iclusig after considering the most recent safety information. We expect that this will provide helpful guidance for patients and healthcare professionals as they consider the treatment options."
The CHMP is a scientific committee composed of representatives from the 28-member states of the EU, and Iceland and Norway. The CHMP reviews medical product applications on their scientific and clinical merit and provides advice to the European Commission, which has the authority to approve medicines for the EU.
CML is a cancer of the white blood cells that is diagnosed in approximately 7,000 patients each year in Europe([1]) . CML and Ph+ ALL patients treated with tyrosine kinase inhibitors (TKIs) can develop resistance or intolerance over time to these therapies. Iclusig is a targeted cancer medicine discovered and developed at ARIAD. It was designed by ARIAD scientists using ARIAD's platform of computational chemistry and structure-based drug design to inhibit BCR-ABL, including drug-resistant mutants that arise during treatment. Iclusig is the only TKI that has been approved/received a marketing authorisation for an indication that includes CML and Ph+ ALL patients with the T315I mutation.
About CML and Ph+ ALL
CML is characterized by an excessive and unregulated production of white blood cells by the bone marrow due to a genetic abnormality that produces the BCR-ABL protein. After a chronic phase of production of too many white blood cells, CML typically evolves to the more aggressive phases referred to as accelerated phase and blast crisis. Ph+ ALL is a subtype of acute lymphoblastic leukaemia that carries the Ph+ chromosome that produces BCR-ABL. It has a more aggressive course than CML and is often treated with a combination of chemotherapy and tyrosine kinase inhibitors. The BCR-ABL protein is expressed in both of these diseases.
Do we have any idea when we might hear the EU verdict? Is it legitimate to expect to hear their ruling tonight, or tomorrow, or next week? TIA.
ECT is waking up; the bottom is in for this dividend cycle. The ride up to the next dividend begins today. Hope you all are on board. The stock should go up to about $9.00 or $9.50 this cycle.
If fed bond purchases remain at 85 billion a month with no planned let up in sight, gold should pop again. If it remains the same but with a planned reduction in sight, it will pop a little. If they reduce bond purchases this month, gold will drop. I think the first scenario is the most likely.
Most of my shares were bought in the mid-20's. My current average is about .215. I keep buying to lower my average.
Indeed; and rise with the share price if it should go that way.
Right on cue...they're bringing things down before the minutes are released, and some scared investors are jumping out to de-risk. Get ready for a strong move upward in 1.25 hours.
Don't take my word for it...look at the previous responses to the FOMC minutes the past 3 months. In October it spiked $10.00/share in one day; in September it spiked $22.00/share in two days; in August it spiked $14.00 in two days.
$12.00 in one day is not that large a spike for NUGT. Wait and see...only 2 hours to go.
It should run at about 2pm EST. Wait and see. Hopefully we get another run like the last two months after the release of the FOMC minutes. If it runs like in the past, the price should spike to somewhere between 48 and $51 later today and early tomorrow. GLTAL.
If that happens I'll be buying a couple hundred thousand more shares putting me over 1 million for now.
I hope everyone is getting in today. Interest is going to rise immensely in this stock in the next couple days. GLTAL.
LOL! Most of the time I buy the stock immediately tanks. This is quite unusual! Liking it. Will sell likely later today.
So far so good. Time will tell.
Good advice. Thanks. Just bought some at 37.9.
If I remember right, didn't the minutes cause a momentary spike in the gold sector (gold, miners, nugt, etc)? If so, I might start a position this morning and sell at the end of the day. Do you see any feasibility to my speculations/predictions?
Do you think there will be anything revealed in the FOMC minutes to provide a positive catalyst to the gold price?
Anticipation of tomorrow's meeting, and subsequent news, should drive the share price up. GLTAL.
Tomorrow marks 5 weeks since the MSJ hearing. Statistically, the judge's decision is just around the corner. Get ready for it! Cheers all.
Do we know within an hour or two when the EU will render their decision?
I'm averaged in at $21 and waiting for a bounce this week. It won't be long and the stock will be back above $25.00/share.
Patience...it will bounce higher. They are shaking out all the shares they can. Load up here. Next week will be a North-bound week. They have already shaken out a lot of people. Selling has nearly stopped. It is about time to move up again.
I think you're right on the bounce here. I got in at 18.9 today. Tomorrow should be profitable for bouncers.
GLTA
From a pure trading standpoint, the stock is coiling. Someone is holding is right where it is while someone else is loading up. I would expect that it starts slowly heading North in the next week. JMO; I've been wrong before!
It is MM's playing games. I cannot tell you how many times I have bought or sold shares over the past year in this stock, and each time they partially fill my order (very partially; maybe 1% of it) and then leave me hanging out to dry so I have to pay another purchase fee later on. Just be patient and wait for it to fill, or hit the ask.
Anyone see a chance this stock rises back to $15 or $16 in the next week, or do you think it will keep slowly dropping from current levels? TIA.
lol! you are right. Patience will pay here; think in terms of weeks and months rather than hours and minutes.
Get ready for a nice, slow uptrend for a while. Today is just the beginning of that trend.
If anyone was short, they will be covering as soon as they can. And they will have to buy quickly, because plenty more of us are going to be buying at the 9:30am buzzer.
Cheers all. Things are finally starting to look up for ARIA after several weeks of pure disappointment.
What Worlds has lacked in the past is some direction about the future. Today's interview provided us some direction, and it gives investors a more long-term perspective on the stock. The word is slowly getting out; time for WDDD to go up!
Cheers all.
Then we just have to agree to disagree. I think Wall Street will like this news and start moving the price up.
We will know more with time.
I agree. I think today's news, unless something is said which contradicts it, provides us a basis for a slow and steady move Northward in share price. There is no longer a reason why this stock should be trading under $5 or $6 short term, and below $10 more longer term (12-18 months).
Cheers all.
They have enough cash and cash equivalents to fund operations through mid-2015. That's 1.5 years. That was enough for me; I'm staying all in as the likelihood that ARIA returns to double digit share price levels in the next 12 months just became fairly high. INTERPRETATION: ARIA will have no need of a public offering in the next 12 months!
At this point in the game, a financial plan and hints about the pipeline are impactful. The stock is way down due in part to unsurety of the future. Investor confidence will return the moment the future is laid out, even if that future looks less than great. Uncertainty is far worse for stocks than negativity; right now there is much uncertainty. JMO.